Selection Bias < Selegiline < Selenium

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 45.
[0-20] [0 - 20][0 - 45][20-40]

Ident.	Authors (with country if any)	Title
000007 (1999)	A. Churchyard [Royaume-Uni] ; C J Mathias ; A J Lees	Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.
000045 (1999)	R B Innis [États-Unis] ; K L Marek ; K. Sheff ; S. Zoghbi ; J. Castronuovo ; A. Feigin ; J P Seibyl	Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.
000272 (2000)	R A Hauser [États-Unis] ; W C Koller ; J P Hubble ; T. Malapira ; K. Busenbark ; C W Olanow	Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
000719 (2002)	Christopher G. Goetz [États-Unis] ; Sue Leurgans ; Rema Raman	Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease.
000737 (2002)	Manavdeep Grewal [Canada] ; Raed Hawa ; Colin Shapiro	Treatment of periodic limb movements in sleep with selegiline HCl.
000865 (2002)		MAO-B inhibitors for the treatment of Parkinson's disease.
000C97 (2004)	Susan Hollán [Hongrie] ; Lászl Vécsei ; Kálmán Magyar	Adverse effects of dopamine potentiation by long-term treatment with selegiline.
000D95 (2004)	Cheryl H. Waters [États-Unis] ; Kapil D. Sethi ; Robert A. Hauser ; Eric Molho ; John M. Bertoni	Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
000E08 (2004)	Carl E. Clarke [Royaume-Uni]	A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
001087 (1992)	M A Mena [Espagne] ; B. Pardo ; M J Casarejos ; S. Fahn ; J. García De Yébenes	Neurotoxicity of levodopa on catecholamine-rich neurons.
001217 (2005)	Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol ; Cristina Sampaio	Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
001219 (2005)	Cheryl Waters [États-Unis]	Other pharmacological treatments for motor complications and dyskinesias.
001457 (1992)	D. Bravi [États-Unis] ; J J Anderson ; F. Dagani ; T L Davis ; R. Ferrari ; M. Gillespie ; T N Chase	Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
001B76 (2007)	Tua Annanmaki [Finlande] ; Antti Muuronen ; Kari Murros	Low plasma uric acid level in Parkinson's disease.
001F74 (2008)	Connie Marras [Canada] ; Michael P. Mcdermott ; Paula A. Rochon ; Caroline M. Tanner ; Gary Naglie ; Anthony E. Lang	Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.
002892 (2009)	Connie Marras [Canada] ; Anthony E. Lang ; Shirley W. Eberly ; David Oakes ; Stanley Fahn ; Steven R. Schwid ; Christopher Hyson ; Ira Shoulson	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
002D19 (2010)	Alessandro Rotondo ; Domenico Bosco ; Massimiliano Plastino ; Arturo Consoli ; Francesca Bosco	Clozapine for medication-related pathological gambling in Parkinson disease.
003E34 (2013)	Radu Constantinescu [États-Unis] ; Jordan Elm [États-Unis] ; Peggy Auinger [États-Unis] ; Saloni Sharma [États-Unis] ; Erika F. Augustine [États-Unis] ; Laith Khadim [États-Unis] ; Karl Kieburtz [États-Unis]	Malignant Melanoma in Early-Treated Parkinson's Disease: The NET-PD Trial
004566 (1987)	J G De Yebenes [États-Unis] ; S. Fahn ; S. Lovelle ; V. Jackson-Lewis ; P. Jorge ; M A Mena ; J. Reiriz ; J C Bustos ; C. Magari Os ; A. Martinez	Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
004595 (1986)	D B Calne [Canada] ; U K Rinne	Controversies in the management of Parkinson's disease.
004728 (1995)	S. Przedborski [États-Unis] ; V. Jackson-Lewis ; S. Fahn	Antiparkinsonian therapies and brain mitochondrial complex I activity.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i -k "Selegiline" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i  \
                -Sk "Selegiline" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Selegiline
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024